4 out of 5 U.S. Employees Rank Lifestyle Change Support as One of the Most Important Factors to Consider with Weight-Loss Drugs, New Survey Reveals
July 16 2024 - 8:00AM
A recent survey conducted by Wondr Health, an industry leader in
behavior-change programs for weight and obesity management,
highlighted lifestyle change support as a top factor individuals
consider when taking a weight-loss drug. While consumer demand for
GLP-1 drugs remains a hot topic, these findings are especially
relevant for employers as they evaluate 2025 wellness benefits that
are cost-effective, deliver measurable results, and meet the
diverse needs of their workforce.
Wondr Health conducted the survey in June and asked individuals
to identify and multi-select which factors are most important to
consider when taking weight-loss medications. 775 Wondr Health
participants across 50+ employer and health plan clients responded
ranking the following factors in order of importance:
- Lifestyle change
support – 77.9%
- Medical supervision
– 69.9%
- Overall
effectiveness – 69.3%
- Potential side
effects – 69.2%
- Loss of muscle
tissue – 63.5%
- Cost – 57.3%
- Potential to regain
weight – 54.7%
- Emotional health
support – 54.5%
- FDA approval –
38.6%
- Implications for
long-term use – 34.3%
“When it comes to engagement and outcomes, the findings from
this survey support our published research that shows participants
who consistently use the Wondr program over a 12-month period
achieve clinically significant weight loss and are able to sustain
it,” said Tim Church, MD, MPH, PhD, Chief Medical Officer, Wondr
Health. “People will put in the work to lose weight and improve
their health when they have access to lifestyle change support
personalized for their individual needs.”
Regardless of where employers land on GLP-1 drug coverage,
behavior change is the foundation for improving and sustaining
health outcomes. Today, over 1,000 employers and 80 health plans
have added the Wondr behavior-change program to benefit plans for
10 million people. In 2023, Wondr expanded its capabilities to
provide clinical support, tailored medication management, and
prescribing for employers who cover GLP-1s and other weight-loss
drugs.
“Employers have more options than just covering GLP-1s to treat
obesity,” said Scott Paddock, Chief Executive Officer, Wondr
Health. “With a proven behavior-change program alone, employers
will significantly improve the health of their workforce and can
expect a 2.1x ROI from Wondr.”
For more information about how Wondr works for employers, visit
https://wondrhealth.com/partners/employers/.
ABOUT WONDR HEALTHWondr Health improves access to
digital, evidence-based behavioral support for full-spectrum weight
and obesity management. Born in the benefits space 15+ years ago,
Wondr is a clinically proven behavior-change program that treats
the root cause of chronic metabolic conditions to improve quality
of life and health outcomes, and prevent and reduce costs. Powered
by data-driven engagement expertise and personalized programming,
and supported by expert content and coaching, Wondr helps everyone
achieve long-term weight loss, improve movement, reduce stress and
anxiety, build healthy eating habits, get better sleep, and more. A
flexible and scalable program, Wondr is the foundation with
advanced clinical capabilities, including tailored prescribing and
medication management, for organizations who cover weight-loss
drugs. For more information, visit www.wondrhealth.com.
###
Trent Freeman
Innsena for Wondr Health
7733305540
wondr@innsena.com